Kaposi Sarcoma–Associated Herpesvirus Episode Characteristics of Study Participantsa
| Episode Summary . | Total . | HIV+/KS− . | HIV−/KS− . | HIV+/KS+ . | HIV−/KS+ . |
|---|---|---|---|---|---|
| Total No. of episodesa | 230 | 59 | 29 | 129 | 13 |
| No. of episodes per participant, median (range) | 2 (1–6) | 1 (1–6) | 1 (1–5) | 2 (1–6) | 1 (1–2) |
| Episode-level summaries | |||||
| Episodes with well-defined durationb | 102 (44) | 23 (39) | 13 (45) | 63 (49) | 3 (23) |
| Episode duration, d (naivec), median (range) | 3 (1–35) | 5 (1–29) | 5 (1–28) | 2 (1–35) | 10 (1–28) |
| Episodes of 1-d duration | 83 (36) | 20 (34) | 8 (28) | 52 (40) | 3 (23) |
| Minimum log10 copies/mL per episode, median (IQR) | 2.6 (0.0–5.8) | 2.7 (0.0–5.8) | 2.8 (0.0–4.7) | 2.5 (0.0–5.1) | 2.7 (0.0–3.0) |
| Maximum log10 copies/mL per episode, median (IQR) | 3.7 (2.2–7.9) | 4.1 (2.3–7.9) | 4.1 (2.3–7.7) | 3.2 (2.2–7.0) | 4.5 (2.8–6.1) |
| Median log10 copies/mL per episode, median (IQR) | 3.1 (2.2–6.4) | 3.4 (2.3–6.4) | 3.6 (2.3–5.7) | 3.0 (2.2–6.1) | 3.4 (2.6–4.6) |
| Participant-level summaries, using episode with maximum observed duration per participant | |||||
| No. of participants | 117 | 36 | 16 | 56 | 9 |
| Episodes with well-defined durationb | 36 (31) | 9 (25) | 4 (25) | 22 (39) | 1 (11) |
| Episode duration, d (naivec), median (range) | 9 (1–35) | 10 (1–29) | 8 (1–28) | 8 (1–35) | 13 (1–28) |
| Episodes of 1-d duration | 21 (18) | 7 (19) | 3 (19) | 10 (18) | 1 (11) |
| Minimum log10 copies/mL per episode, median (IQR) | 2.5 (0.0–5.8) | 2.6 (0.0–5.8) | 1.3 (0.0–4.4) | 1.1 (0.0–4.9) | 2.7 (0.0–3.0) |
| Maximum log10 copies/mL per episode, median (IQR) | 4.5 (2.2–7.9) | 4.8 (2.6–7.9) | 5.0 (2.6–7.7) | 4.0 (2.2–7.0) | 4.8 (3.0–6.1) |
| Median log10 copies/mL per episode, median (IQR) | 3.4 (2.2–6.4) | 3.7 (2.5–6.4) | 3.7 (2.3–5.7) | 3.2 (2.2–6.1) | 3.5 (2.6–4.6) |
| Episode Summary . | Total . | HIV+/KS− . | HIV−/KS− . | HIV+/KS+ . | HIV−/KS+ . |
|---|---|---|---|---|---|
| Total No. of episodesa | 230 | 59 | 29 | 129 | 13 |
| No. of episodes per participant, median (range) | 2 (1–6) | 1 (1–6) | 1 (1–5) | 2 (1–6) | 1 (1–2) |
| Episode-level summaries | |||||
| Episodes with well-defined durationb | 102 (44) | 23 (39) | 13 (45) | 63 (49) | 3 (23) |
| Episode duration, d (naivec), median (range) | 3 (1–35) | 5 (1–29) | 5 (1–28) | 2 (1–35) | 10 (1–28) |
| Episodes of 1-d duration | 83 (36) | 20 (34) | 8 (28) | 52 (40) | 3 (23) |
| Minimum log10 copies/mL per episode, median (IQR) | 2.6 (0.0–5.8) | 2.7 (0.0–5.8) | 2.8 (0.0–4.7) | 2.5 (0.0–5.1) | 2.7 (0.0–3.0) |
| Maximum log10 copies/mL per episode, median (IQR) | 3.7 (2.2–7.9) | 4.1 (2.3–7.9) | 4.1 (2.3–7.7) | 3.2 (2.2–7.0) | 4.5 (2.8–6.1) |
| Median log10 copies/mL per episode, median (IQR) | 3.1 (2.2–6.4) | 3.4 (2.3–6.4) | 3.6 (2.3–5.7) | 3.0 (2.2–6.1) | 3.4 (2.6–4.6) |
| Participant-level summaries, using episode with maximum observed duration per participant | |||||
| No. of participants | 117 | 36 | 16 | 56 | 9 |
| Episodes with well-defined durationb | 36 (31) | 9 (25) | 4 (25) | 22 (39) | 1 (11) |
| Episode duration, d (naivec), median (range) | 9 (1–35) | 10 (1–29) | 8 (1–28) | 8 (1–35) | 13 (1–28) |
| Episodes of 1-d duration | 21 (18) | 7 (19) | 3 (19) | 10 (18) | 1 (11) |
| Minimum log10 copies/mL per episode, median (IQR) | 2.5 (0.0–5.8) | 2.6 (0.0–5.8) | 1.3 (0.0–4.4) | 1.1 (0.0–4.9) | 2.7 (0.0–3.0) |
| Maximum log10 copies/mL per episode, median (IQR) | 4.5 (2.2–7.9) | 4.8 (2.6–7.9) | 5.0 (2.6–7.7) | 4.0 (2.2–7.0) | 4.8 (3.0–6.1) |
| Median log10 copies/mL per episode, median (IQR) | 3.4 (2.2–6.4) | 3.7 (2.5–6.4) | 3.7 (2.3–5.7) | 3.2 (2.2–6.1) | 3.5 (2.6–4.6) |
Data are presented as No. (%) unless otherwise indicated.
Abbreviations: HIV–, human immunodeficiency virus seronegative; HIV+, human immunodeficiency virus seropositive; IQR, interquartile range; KS–, without Kaposi sarcoma; KS+, with Kaposi sarcoma.
aIncludes only participants with Kaposi sarcoma–associated herpesvirus (KSHV) DNA detected in at least 1 oral swab. Episodes defined by consecutive positive days, allowing 1 or more instances of a single negative or missing value within the string of positives.
bWell-defined duration is defined by episode start preceded by 2 consecutive negatives and episode end followed by 2 consecutive negatives.
cIncluding episodes without well-defined duration, using observed durations. These are likely underestimates.
Kaposi Sarcoma–Associated Herpesvirus Episode Characteristics of Study Participantsa
| Episode Summary . | Total . | HIV+/KS− . | HIV−/KS− . | HIV+/KS+ . | HIV−/KS+ . |
|---|---|---|---|---|---|
| Total No. of episodesa | 230 | 59 | 29 | 129 | 13 |
| No. of episodes per participant, median (range) | 2 (1–6) | 1 (1–6) | 1 (1–5) | 2 (1–6) | 1 (1–2) |
| Episode-level summaries | |||||
| Episodes with well-defined durationb | 102 (44) | 23 (39) | 13 (45) | 63 (49) | 3 (23) |
| Episode duration, d (naivec), median (range) | 3 (1–35) | 5 (1–29) | 5 (1–28) | 2 (1–35) | 10 (1–28) |
| Episodes of 1-d duration | 83 (36) | 20 (34) | 8 (28) | 52 (40) | 3 (23) |
| Minimum log10 copies/mL per episode, median (IQR) | 2.6 (0.0–5.8) | 2.7 (0.0–5.8) | 2.8 (0.0–4.7) | 2.5 (0.0–5.1) | 2.7 (0.0–3.0) |
| Maximum log10 copies/mL per episode, median (IQR) | 3.7 (2.2–7.9) | 4.1 (2.3–7.9) | 4.1 (2.3–7.7) | 3.2 (2.2–7.0) | 4.5 (2.8–6.1) |
| Median log10 copies/mL per episode, median (IQR) | 3.1 (2.2–6.4) | 3.4 (2.3–6.4) | 3.6 (2.3–5.7) | 3.0 (2.2–6.1) | 3.4 (2.6–4.6) |
| Participant-level summaries, using episode with maximum observed duration per participant | |||||
| No. of participants | 117 | 36 | 16 | 56 | 9 |
| Episodes with well-defined durationb | 36 (31) | 9 (25) | 4 (25) | 22 (39) | 1 (11) |
| Episode duration, d (naivec), median (range) | 9 (1–35) | 10 (1–29) | 8 (1–28) | 8 (1–35) | 13 (1–28) |
| Episodes of 1-d duration | 21 (18) | 7 (19) | 3 (19) | 10 (18) | 1 (11) |
| Minimum log10 copies/mL per episode, median (IQR) | 2.5 (0.0–5.8) | 2.6 (0.0–5.8) | 1.3 (0.0–4.4) | 1.1 (0.0–4.9) | 2.7 (0.0–3.0) |
| Maximum log10 copies/mL per episode, median (IQR) | 4.5 (2.2–7.9) | 4.8 (2.6–7.9) | 5.0 (2.6–7.7) | 4.0 (2.2–7.0) | 4.8 (3.0–6.1) |
| Median log10 copies/mL per episode, median (IQR) | 3.4 (2.2–6.4) | 3.7 (2.5–6.4) | 3.7 (2.3–5.7) | 3.2 (2.2–6.1) | 3.5 (2.6–4.6) |
| Episode Summary . | Total . | HIV+/KS− . | HIV−/KS− . | HIV+/KS+ . | HIV−/KS+ . |
|---|---|---|---|---|---|
| Total No. of episodesa | 230 | 59 | 29 | 129 | 13 |
| No. of episodes per participant, median (range) | 2 (1–6) | 1 (1–6) | 1 (1–5) | 2 (1–6) | 1 (1–2) |
| Episode-level summaries | |||||
| Episodes with well-defined durationb | 102 (44) | 23 (39) | 13 (45) | 63 (49) | 3 (23) |
| Episode duration, d (naivec), median (range) | 3 (1–35) | 5 (1–29) | 5 (1–28) | 2 (1–35) | 10 (1–28) |
| Episodes of 1-d duration | 83 (36) | 20 (34) | 8 (28) | 52 (40) | 3 (23) |
| Minimum log10 copies/mL per episode, median (IQR) | 2.6 (0.0–5.8) | 2.7 (0.0–5.8) | 2.8 (0.0–4.7) | 2.5 (0.0–5.1) | 2.7 (0.0–3.0) |
| Maximum log10 copies/mL per episode, median (IQR) | 3.7 (2.2–7.9) | 4.1 (2.3–7.9) | 4.1 (2.3–7.7) | 3.2 (2.2–7.0) | 4.5 (2.8–6.1) |
| Median log10 copies/mL per episode, median (IQR) | 3.1 (2.2–6.4) | 3.4 (2.3–6.4) | 3.6 (2.3–5.7) | 3.0 (2.2–6.1) | 3.4 (2.6–4.6) |
| Participant-level summaries, using episode with maximum observed duration per participant | |||||
| No. of participants | 117 | 36 | 16 | 56 | 9 |
| Episodes with well-defined durationb | 36 (31) | 9 (25) | 4 (25) | 22 (39) | 1 (11) |
| Episode duration, d (naivec), median (range) | 9 (1–35) | 10 (1–29) | 8 (1–28) | 8 (1–35) | 13 (1–28) |
| Episodes of 1-d duration | 21 (18) | 7 (19) | 3 (19) | 10 (18) | 1 (11) |
| Minimum log10 copies/mL per episode, median (IQR) | 2.5 (0.0–5.8) | 2.6 (0.0–5.8) | 1.3 (0.0–4.4) | 1.1 (0.0–4.9) | 2.7 (0.0–3.0) |
| Maximum log10 copies/mL per episode, median (IQR) | 4.5 (2.2–7.9) | 4.8 (2.6–7.9) | 5.0 (2.6–7.7) | 4.0 (2.2–7.0) | 4.8 (3.0–6.1) |
| Median log10 copies/mL per episode, median (IQR) | 3.4 (2.2–6.4) | 3.7 (2.5–6.4) | 3.7 (2.3–5.7) | 3.2 (2.2–6.1) | 3.5 (2.6–4.6) |
Data are presented as No. (%) unless otherwise indicated.
Abbreviations: HIV–, human immunodeficiency virus seronegative; HIV+, human immunodeficiency virus seropositive; IQR, interquartile range; KS–, without Kaposi sarcoma; KS+, with Kaposi sarcoma.
aIncludes only participants with Kaposi sarcoma–associated herpesvirus (KSHV) DNA detected in at least 1 oral swab. Episodes defined by consecutive positive days, allowing 1 or more instances of a single negative or missing value within the string of positives.
bWell-defined duration is defined by episode start preceded by 2 consecutive negatives and episode end followed by 2 consecutive negatives.
cIncluding episodes without well-defined duration, using observed durations. These are likely underestimates.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
